Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study

Moon, Seok Whan; Choi, Si Young; Moon, Myung Sang

doi:10.21037/jtd.2018.06.09

Cited by 21 publications

(38 citation statements)

References 23 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Simultaneously, the term “invasive mucinous adenocarcinoma (IMA)” was proposed to replace the previously named mucinous bronchoalveolar adenocarcinoma [ 3 ]. According to the report, IMA accounts for 0.2% of all primary lung cancer [ 4 ], and < 2–10% of all lung adenocarcinomas [ 5 ], thus it is considered as a relatively rare histologic subtype.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, a study by Yoshizawa et al showed that the disease-free survival of patients with IMA were between low-grade and high-grade adenocarcinoma [ 10 ]. A recent study indicated that the survival curve of IMA patients was between lepidic adenocarcinoma and other adenocarcinoma patients, and it found that ~ 70% of IMAs were either stage I or II at the time of diagnosis [ 4 ]. Similarly, Warth et al found that a better prognosis was available for IMA patients compared with most adenocarcinoma patients [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database

et al. 2021

View full text Add to dashboard Cite

Background Lung cancer remains the leading cause of cancer death globally. In 2015, the cancer classification guidelines of the World Health Organization were updated. The term “invasive mucinous adenocarcinoma (IMA)” aroused people’s attention, while the clinicopathological factors that may influence survival were unclear. Methods Data of IMA patients was downloaded from SEER database. Kaplan-Meier methods and log-rank tests were used to compare the differences in OS and LCSS. The nomogram was developed based on the result of the multivariable analysis. The discrimination and accuracy were tested by Harrell’s concordance index (C-index), receiver operating characteristic (ROC) curve, calibration curve and decision curve analyses (DCA). Integrated discrimination improvement (IDI) index was used to evaluate the clinical efficacy. Results According to multivariate analysis, the prognosis of IMAs was associated with age, differentiation grade, TNM stage and treatments. Surgery might be the only way that would improve survival. Area under the curve (AUC) of the training cohort was 0.834and 0.830 for3-and 5-year OS, respectively. AUC for 3-and 5-year LCSS were separately 0.839 and 0.839. The new model was then evaluated by calibration curve, DCA and IDI index. Conclusion Based on this study, prognosis of IMAs was systematically reviewed, and a new nomogram was developed and validated. This model helps us understand IMA in depth and provides new ideas for IMA treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, patients with IMA tended to have an earlier tumor stage than those with other types of lung ADC [6]. Another study demonstrated that in stage IV cases, patients with IMA frequently had lower lobe tumor mass, initial bilateral lung involvement, and pneumonia-like consolidation on chest tomography [5,7].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma

Gow

Hsieh

Liu

et al. 2021

Cancers

View full text Add to dashboard Cite

Pulmonary invasive mucinous adenocarcinoma (IMA) has unique histological patterns. This study aimed to comprehensively evaluate the clinicopathological features, prognosis, and survival outcomes of IMAs. We retrospectively identified 77 patients with pulmonary IMA and reviewed their clinical and pathological features. Another 520 patients with non-IMA-type ADC were retrieved for comparison with patients with IMA. A new two-tier grading system (high-grade and low-grade IMAs) modified from the pancreatic intraepithelial neoplasia classification system was used for survival analyses. Compared to patients with non-IMA-type ADC, patients with IMA tended to have never smoked (p = 0.01) and had early-stage IMA at initial diagnosis (p < 0.001). For stage I–II diseases, the five-year overall survival (OS) rates were 76% in IMAs and 50% in non-IMA-type ADCs, and a longer OS was observed in patients with IMA (p = 0.002). KRAS mutations were the most commonly detected driver mutations, which occurred in 12 of the 28 (43%) patients. High-grade IMAs were associated with a shorter recurrence-free survival (RFS) for stage I–IIIA diseases (p = 0.010) than low-grade IMAs but not for OS. In conclusion, patients with stage I and II IMA had better OS than those with non-IMA-type ADC. A new two-tier grading system might be useful for predicting RFS in stage I–IIIA IMAs.

show abstract

“…Patients with IMA lesions showing acinar-predominant features on computed tomography (CT) exhibit a poorer prognosis [ 9 ]. Some studies have suggested that patients with a surgically resected IMA have similar overall survival (OS) outcomes to non-mucinous adenocarcinoma cases [ 10 , 11 ]. In patients with metastatic IMA, there was no difference found in a previous report between IMA and non-mucinous adenocarcinoma patients [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung

et al. 2021

View full text Add to dashboard Cite

Background A primary pulmonary invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive adenocarcinoma of the lung. The prognosis of advanced IMA depending on chemotherapy regimen has not been fully investigated. Here, we compared the clinical outcomes of patients with advanced IMA treated with different palliative chemotherapies that included novel therapeutics. Methods This single-center retrospective study included a total of 79 patients diagnosed with IMA and treated with palliative chemotherapy. The primary outcome was the comparison of overall survival according to palliative chemotherapy type. Risk factors associated with death were evaluated as a secondary outcome. Results The study cohort of 79 patients comprised 27 progressive or recurrent cases and 52 initial metastatic patients. Thirteen patients (16.5%) received targeted therapy and 18 cases (22.8%) received immunotherapy. When we compared the survival outcomes of the different treatment regimens, patients with IMA treated by immunotherapy (undefined vs. non-immunotherapy 17.0 months, p < 0.001) had better overall survival rates. However, there was no difference in the prognosis between the cases treated with a targeted therapy (35.6 vs. non-targeted therapy 17.0 months, p = 0.211). None of the conventional regimens produced a better outcome. By multivariable analysis, immunotherapy (HR 0.28; 95% CI 0.11–0.74; P = 0.008) was found to be an independent prognostic factor for death. Conclusions This study suggests that immunotherapy for patients with advanced IMA may provide favorable outcomes than other chemotherapy options.

show abstract

Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study

Cited by 21 publications

References 23 publications

Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database

Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database

Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung

Contact Info

Product

Resources

About